Posted by Michael Wonder on 01 Jun 2022
Apellis announces submission of new drug application to the FDA for pegcetacoplan for geographic atrophy
1 June 2022 - Apellis Pharmaceuticals today announced that the company has submitted a new drug application to the United States FDA for intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy secondary to age-related macular degeneration.
The new drug application submission is based on results from the Phase 3 DERBY and OAKS studies at 12 and 18 months and the Phase 2 FILLY study at 12 months.
